Amisulpride and olanzapine combo as an alternative to monotherapy in schizophrenia? Study sheds light
Germany: The combination of amisulpride and olanzapine therapy could be used in schizophrenia patients as an alternative to monotherapy in certain clinical situations, but side effects should also be considered, states a recent study. The study appears in the journal The Lancet Psychiatry.
"The advantages of this specific combination have to weighed against a higher propensity for side effects," Christian Schmidt-Kraepelin, and researchers team wrote in their study.
Evidence-based guidelines generally do not recommend combining antipsychotics in schizophrenia treatment despite it being a common practice. Otherwise, evidence remains inconclusive particularly regarding specific combinations. Dr. Schmidt-Kraepelin and the team aimed to test whether a combination of amisulpride plus olanzapine is more effective than either intervention as a monotherapy.
For this purpose, the researchers conducted a 16-week, randomised, double-blind, controlled trial at 16 psychiatric in-patient centres throughout Germany. The trial included adults adults aged 18–65 years with non-first episode schizophrenia or schizoaffective disorder and with a Positive and Negative Syndrome Scale (PANSS) total score of at least 70 and at least two items of the positive symptoms subscale rated at least 4. They were randomly assigned to receive 16 weeks of treatment with either amisulpride plus olanzapine, amisulpride plus placebo, or olanzapine plus placebo (1:1:1).
Comparison was done between flexibly dosed monotherapy of oral amisulpride (amisulpride plus placebo, 200–800 mg per day) or olanzapine (olanzapine plus placebo, 5–20 mg per day) and a combination of amisulpride plus olanzapine. Symptom reduction measured by the PANSS total score after 8 weeks was the primary outcome.
13 692 patients were assessed for eligibility between June 15, 2012, and Dec 15, 2018. 13 364 patients were excluded, and 328 were then randomly assigned to an intervention group. 112 patients were randomly assigned to receive amisulpride plus olanzapine, 109 were randomly assigned to receive amisulpride plus placebo, and 107 were randomly assigned to receive olanzapine plus placebo.
The primary outcome was analyzed in 321 patients. Among the 321 patients who were randomly assigned to intervention groups and analysed for the primary outcome, 229 (71%) were male, 92 (29%) were female; the mean age was 40·2 years; and 296 (92%) were White and 25 (8%) were classified as other ethnicity.
Based on the study, following findings were revealed:
· PANSS total score improved significantly more at 8 weeks in the amisulpride plus olanzapine group (−29·6) than in the olanzapine plus placebo group (−24·1).
· A significant difference was not observed in reduction of PANSS total score between the amisulpride and olanzapine group compared with the amisulpride and placebo group (−25·2).
· After 8 weeks and 16 weeks, sexual dysfunction, weight, and waist circumference increase were significantly higher for patients receiving amisulpride plus olanzapine than for those receiving amisulpride plus placebo, with no differences in serious adverse events.
· Two patients died during study participation; one randomly assigned to the amisulpride plus olanzapine group, and one assigned to the olanzapine plus placebo group (both assessed with no relation to treatment).
The authors wrote, "the advantages of amisulpride plus olanzapine have to be weighed against a higher propensity for side-effects. "This combination therapy could be used an alternative to monotherapy in certain clinical situations, but side-effects should be considered."
Reference:
The study titled, "Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial," was published in the journal The Lancet Psychiatry.
DOI: https://doi.org/10.1016/S2215-0366(22)00032-3
KEYWORDS: Lancet, amisulpride, olanzapine, schizophrenia, antipsychotics, combination therapy, monotherapy, Christian Schmidt-Kraepelin, acutely ill, treatment, side effects
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.